CORE--Shared Resources Proteomics

描述(申请人提供)：癌症中心？S蛋白质组研究所支持 癌症中心？S研究员提供质谱学(MS)和表面等离子体共振(SPR)方面的知识和专业知识。对于对蛋白质鉴定、翻译后修饰、多肽和碳水化合物的表征以及癌细胞蛋白质组的全球研究感兴趣的研究人员来说，MS是一项有价值的技术。SPR提供了对分子相互作用的实时分析。蛋白质组学设施拥有几个质谱仪(MALDI-TOF、ESI-QQQ和Q-TOF)、HPLC、Biacore 3000仪器和相关分析设备。该设施致力于开发和实施技术，使癌症中心的研究人员能够详细分析感兴趣的特定蛋白质，或对与癌症生物学相关的多肽亚集进行更广泛的基于蛋白质组的筛选。 该设施的具体目标是：1.为癌症中心做出贡献？S通过提供高质量的质谱学和表面等离子激元共振方面的服务和专业知识，并继续培训有兴趣的癌症中心研究人员使用我们的仪器和方案。2.保持在蛋白质组学技术进步和机遇的前沿，并使癌症中心的成员了解这些技术的最新情况。3.积极开发新的蛋白质组学技术，并为癌症中心的研究人员提供技术开发的平台。为了协助癌症中心？S通过开发小分子的质谱学协议，发起了新的抗癌药物发现计划。

DESCRIPTION (provided by applicant): The Cancer Center?s Proteomics Facility supports the Cancer Center?s investigators by providing access to and expertise in mass spectrometry (MS) and surface plasmon resonance (SPR). MS is a valuable technology to researchers interested in protein identification, characterization of post-translational modifications, peptides and carbohydrates, as well as global studies of the proteome of cancer cells. SPR provides real-time analysis of molecular interactions. The Proteomics Facility houses several mass spectrometers (MALDI-TOF, ESI-QQQ, and Q-TOF), HPLCs, a BIAcore 3000 instrument, and related analytical equipment. The facility is dedicated to the development and implementation of technology that will allow the Cancer Center investigators to analyze particular proteins on interest in detail or to perform broader proteome-based screens of polypeptide subsets relevant to cancer biology. The Specific Aims for the Facility are: 1. To contribute to the Cancer Center?s research by providing high-quality service and expertise in mass spectrometry and surface plasmon resonance, and to continue to train interested Cancer Center investigators in the use of our instruments and protocols. 2. To stay at the cutting edge of technology advances and opportunities in proteomics, and to keep members of the Cancer Center current in these technologies. 3. To engage in active development of new proteomics techniques, as well as serve as a platform for technology development by Cancer Center investigators. To assist the Cancer Center?s new Cancer Drug Discovery Initiative by developing mass spectrometry protocols for small molecules.